13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001281446
Total reported value
$529.1M
$529.1M
29 檔
23.5%
In Q3 2024, Great Point Partners LLC's U.S. equity holdings reached a combined market value of $529.1M, distributed across 29 disclosed stock positions.
In Q3 2024, Great Point Partners LLC adopted a defensive or profit-taking posture, trimming 19 positions and completely liquidating 9 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NGNE | Neurogene Inc | Stock-Other | 12.40% | -0.23% | — | |
| 2 | ABVX | Abivax Sa-adr | Stock-Other | 7.22% | +15.22% | NEW | |
| 3 | PLRX | Pliant Therapeutics Inc | Stock-Other | 6.30% | — | -27.56% | |
| 4 | EOLS | Evolus Inc | Stock-Other | 5.58% | — | -52.28% | |
| 5 | VRDN | Viridian Therapeutics Inc | Stock-Other | 5.02% | — | +50.00% | |
| 6 | ACLXGBX | Arcellx Inc | Stock-Other | 4.92% | — | -59.35% | |
| 7 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.91% | — | -33.36% | |
| 8 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 4.43% | -3.12% | EXIT | |
| 9 | DVAX | Dynavax Technologies CORP | Stock-Other | 4.35% | — | -44.13% | |
| 10 | CNTX | Context Therapeutics Inc | Stock-Other | 4.00% | -1.35% | EXIT | |
| 11 | ✓ | Zura Bio LTD | Stock-Other | 3.90% | -1.07% | -29.70% | |
| 12 | ORKA | Oruka Therapeutics Inc | Stock-Other | 3.71% | +1.23% | — | |
| 13 | ✓ | Merus N V | Stock-Other | 3.68% | — | -52.23% | |
| 14 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 3.51% | — | +25.49% | |
| 15 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 3.01% | — | -22.73% | |
| 16 | AUTL | Autolus Therapeutics PLC | Stock-Other | 3.00% | — | -18.30% | |
| 17 | URGN | UroGen Pharma Ltd. | Stock-Other | 2.84% | — | -73.89% | |
| 18 | ✓ | Optinose Inc | Stock-Other | 2.54% | — | -6.31% | |
| 19 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.22% | — | -63.72% | |
| 20 | OTLK | Outlook Therapeutics Inc | Stock-Other | 2.03% | — | -24.01% | |
| 21 | JSPR | Jasper Therapeutics Inc | Stock-Other | 1.78% | — | -19.81% | |
| 22 | VYGR | Voyager Therapeutics Inc | Stock-Other | 1.65% | — | -40.06% | |
| 23 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 1.54% | — | — | |
| 24 | TCRX | Tscan Therapeutics Inc | Stock-Other | 1.49% | — | +8.03% | |
| 25 | ✓ | Stock-Other | 1.03% | — | — | ||
| 26 | PMNEUR | Promis Neurosciences Inc | Stock-Other | 1.03% | — | — | |
| 27 | RNAC | Cartesian Therapeutics Inc | Stock-Other | 0.95% | — | — | |
| 28 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.60% | — | -55.92% | |
| 29 | CLYM | Climb Bio Inc | Stock-Other | 0.37% | +0.36% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NGNE | Neurogene Inc | +5.4% | — | Unchanged |
| 2 | VRDN | Viridian Therapeutics Inc | +3.8% | +50.00% | Add |
| 3 | ORKA | Oruka Therapeutics Inc | +3.7% | NEW | New buy |
| 4 | OLMA | Olema Pharmaceuticals Inc | +1.9% | +25.49% | Add |
| 5 | 4XC1 | Kalvista Pharmaceuticals Inc | +1.4% | -2.92% | Trim |
| 6 | CNTX | Context Therapeutics Inc | +1.2% | -6.53% | Trim |
| 7 | ✓ | +1% | NEW | New buy | |
| 8 | PMNEUR | Promis Neurosciences Inc | +1% | NEW | New buy |
| 9 | ABVX | Abivax Sa-adr | +1% | -13.89% | Trim |
| 10 | RNAC | Cartesian Therapeutics Inc | +1% | NEW | New buy |
| 11 | PLRX | Pliant Therapeutics Inc | +0.9% | -27.56% | Trim |
| 12 | ✓ | Zura Bio LTD | +0.8% | -29.70% | Trim |
| 13 | AUTL | Autolus Therapeutics PLC | +0.7% | -18.30% | Trim |
| 14 | ✓ | Helix Acquisition CORP Ii | +0.6% | — | Unchanged |
| 15 | EOLS | Evolus Inc | +0.5% | -52.28% | Trim |
| 16 | TCRX | Tscan Therapeutics Inc | +0.4% | +8.03% | Add |
| 17 | CLYM | Climb Bio Inc | +0.4% | NEW | New buy |
| 18 | JSPR | Jasper Therapeutics Inc | 0% | -19.81% | Trim |
| 19 | IONS | Ionis Pharmaceuticals Inc | — | -22.73% | Trim |
| 20 | CYTK | Cytokinetics Inc | 0% | -33.36% | Trim |
| 21 | LXRX | Lexicon Pharmaceuticals Inc | 0% | EXIT | Sold out |
| 22 | ANAB | Anaptysbio Inc | -0.1% | EXIT | Sold out |
| 23 | ✓ | Optinose Inc | -0.2% | -6.31% | Trim |
| 24 | ACLXGBX | Arcellx Inc | -0.3% | -59.35% | Trim |
| 25 | OTLK | Outlook Therapeutics Inc | -0.4% | -24.01% | Trim |
| 26 | VTGN | Vistagen Therapeutics Inc | -0.4% | -55.92% | Trim |
| 27 | SYRE | Spyre Therapeutics Inc | -0.6% | EXIT | Sold out |
| 28 | KYTX | Kyverna Therapeutics Inc | -0.7% | EXIT | Sold out |
| 29 | DVAX | Dynavax Technologies CORP | -0.8% | -44.13% | Trim |
| 30 | VYGR | Voyager Therapeutics Inc | -0.8% | -40.06% | Trim |
| 31 | PBYI | Puma Biotechnology Inc | -0.9% | EXIT | Sold out |
| 32 | 430 | Terns Pharmaceuticals Inc | -1.5% | EXIT | Sold out |
| 33 | DNTH | Dianthus Therapeutics Inc | -1.5% | -63.72% | Trim |
| 34 | ✓ | Merus N V | -2.3% | -52.23% | Trim |
| 35 | ESPR | Esperion Therapeutics Inc | -2.5% | EXIT | Sold out |
| 36 | AM6 | Amicus Therapeutics Inc | -2.8% | EXIT | Sold out |
| 37 | INSM | Insmed Inc | -3.2% | EXIT | Sold out |
| 38 | URGN | UroGen Pharma Ltd. | -6.5% | -73.89% | Trim |
According to official SEC Form 13F filings, Great Point Partners LLC reported a total U.S. public equity portfolio value of $529.1M across 29 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NGNE, ABVX, PLRX) accounted for 23.5% of total reported equity market value during Q3 2024.
Top New Position Initiated
ORKA
市值: $12.6M
Top Position Liquidated / Trimmed
INSM
前期市值: $16.8M
During Q3 2024, Great Point Partners LLC's top holdings by market value included NGNE (12.4%)、ABVX (7.2%)、PLRX (6.3%). The largest single position, NGNE, represented 12.4% of total portfolio value.
In Q3 2024, Great Point Partners LLC made 36 total portfolio adjustments, initiating 5 new buys, adding to 3 positions, trimming 19 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.